Anti-amyloid immunotherapies for Alzheimer's disease: Administration, side effects, and overall framework. — Recently, the Food and Drug Administration (FDA) approved the use of aducanumab (Aduhelm), lecanemab (Leqembi), and donanemab (Kisunla) in patients with mild cognitive impairment (MCI) and early-stage...

Evidence span

Anti-amyloid immunotherapies for Alzheimer's disease: Administration, side effects, and overall framework. — Recently, the Food and Drug Administration (FDA) approved the use of aducanumab (Aduhelm), lecanemab (Leqembi), and donanemab (Kisunla) in patients with mild cognitive impairment (MCI) and early-stage...

From Sadruddin Z et al. 2025, Geriatric nursing (New York, N.Y.)

Method & conditions

Evidence type

experimental

Method

manual state transition; control details require source inspection

Species

Homo sapiens

Conditions

Humans; Alzheimer Disease; Immunotherapy; United States; Antibodies, Monoclonal, Humanized — Geriatric nursing (New York, N.Y.) 2025

Replicated

not yet

Confidence basis

operator-supplied frontier prior; review required